Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

Ophthalmologist recommends alternative therapy for Graves' eye disease

Don Parker was facing a second surgery to treat the bulging eyes and double vision he was experiencing due to Graves' eye disease.

10 Jul 2014

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

The American Academy of Ophthalmology – the world's largest association of eye physicians and surgeons – is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma.

28 Jun 2014

University of Utah researcher to receive Nelson Trust Award for Retinitis Pigmentosa

Research to Prevent Blindness, a New York-based foundation, has announced that University of Utah researcher Wolfgang Baehr, Ph.D., will receive the Nelson Trust Award for Retinitis Pigmentosa-and an accompanying $100,000 to pursue new scientific leads to understand contributors to blindness.

27 Jun 2014

State roundup: Troubles in Kentucky; MD. hospital under review

The team at The Upshot, a Times news and data-analysis venture, compiled six basic metrics to give a picture of the quality and longevity of life in each county of the nation: educational attainment, household income, jobless rate, disability rate, life expectancy and obesity rate.

27 Jun 2014

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

23 Jun 2014

Simulator for evaluating effects of visual impairment on person's driving performance

The University of California, San Diego School of Medicine is the first ophthalmology department in the nation to feature a fully dedicated high-fidelity, highly realistic driving simulator for evaluating the effects of visual impairment on a person's driving performance.

16 Jun 2014

Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

Patients with type 2 diabetes who take a combination of metformin plus insulin may be at higher risk for cardiovascular disease and death compared with those who take a combination of metformin plus sulfonylurea, according to a new study funded by the Agency for Healthcare Research and Quality that appears in the June 11 issue of JAMA.

11 Jun 2014

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease.

6 Jun 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.

19 May 2014

Researchers develop potential route to new therapies for treatment of Parkinson's disease

A biologist and a psychologist at the University of York have joined forces with a drug discovery group at Lundbeck in Denmark to develop a potential route to new therapies for the treatment of Parkinson's Disease (PD).

16 May 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014

Scientists develop non-invasive technique to determine gene carriers for retinitis pigmentosa

Scientists have developed a non-invasive technique to determine if individuals carry a gene for an inherited eye disease known as retinitis pigmentosa.

9 May 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2014.

7 May 2014

New research aids development of better treatments for dry eye

The eye is an exquisitely sensitive system with many aspects that remain somewhat of a mystery-both in the laboratory and in the clinic.

7 May 2014

BrightFocus Foundation honors 5 outstanding scientists in fields of macular degeneration, glaucoma

The BrightFocus Foundation today honored five outstanding scientists in the fields of macular degeneration and glaucoma, presenting them with named research awards at an event during the annual meeting of the Association for Research in Vision and Ophthalmology.

6 May 2014

FDA approves Parion’s investigational new drug application for treatment of dry eye disease

Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.

2 May 2014

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Retinitis pigmentosa (RP) is a progressive eye disease that leads to untreatable blindness. The name of the disease derives from the fact that one of the areas affected by the disease is the retinal pigment epithelium (RPE) in the back of the eye.

30 Apr 2014

Free educational event for patients with Graves' disease and thyroid eye disease

The Massachusetts Eye and Ear and the Graves' Disease & Thyroid Foundation will host a free educational event for patients living with Graves' disease and thyroid eye disease on Saturday, May 10 from 8:30 a.m. to noon at Mass. Eye and Ear's Meltzer Auditorium, 3rd floor, 243 Charles Street, Boston, Mass., 02114.